SAN FRANCISCO — Earlier this month, numerous drug makers began raising prices after taking a hiatus last summer under political pressure from President Trump. Even so, the vast majority of recent price hikes were low single-digit increases, although there were a couple of notable exceptions. One was Allergan (AGN), whose chief executive, Brent Saunders, famously declared in September 2016 that his company would keep a “social contract” by ensuring price hikes — after paying rebates and discounts — would remain below double digits and not exceed inflation.

The move won him praise, but the newest increases suggested the company was, nonetheless, pushing the proverbial envelope. STAT spoke briefly with Saunders at the J.P. Morgan Healthcare Conference about the decision and his take on the larger pricing problem. This is an edited version.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Re:Allergan drug pricing. They eliminated the COB benefit card at year end 2018 for Rapaflo, so instead of paying $20 for a three month supply, it is now $799 to $950. That’s really a BIG help.

  • I’m no lawyer, but I think when it comes to contract law, “We stuck to the spirit” is not really a good defense when you’re charged with breaching the letter.

  • “Won him praise” from who. They claim to have ” social contract “. Do they have any ” moral contract”. My guess none except to make sure their bonuses are secured through revenue increase that would come from price hikes. They have and will not have affordable drugs for masses that could give them much higher revenue increases.

    Is there something called moral or social responsibility?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy